What is Massive Bio?
Massive Bio operates at the intersection of artificial intelligence and oncology, aiming to bridge the gap between cancer patients and vital clinical trials. The company's AI-powered platform facilitates patient identification and virtual pre-screening, significantly enhancing match rates and streamlining the enrollment process. By controlling the patient enrollment value chain, Massive Bio accelerates drug development timelines and cultivates a valuable oncology data ecosystem for improved protocol design and real-world insights. Serving over two dozen pharmaceutical companies, contract research organizations (CROs), and hospital networks, Massive Bio has also been recognized with an SBIR contract from the National Cancer Institute (NCI) for its Deep Learning Clinical Trial Matching System (DLCTMS). The company was selected for the "Digital Health 100" by New York City Health Business Leaders, highlighting its impact in the digital health sector.
How much funding has Massive Bio raised?
Massive Bio has raised a total of $11.7M across 3 funding rounds:
Other Financing Round
$2.6M
Debt
$74K
Other Financing Round
$9M
Other Financing Round (2020): $2.6M with participation from Revo Capital and Cavendish Impact Foundation
Debt (2021): $74K led by PPP
Other Financing Round (2022): $9M supported by Revo Capital
Key Investors in Massive Bio
Revo Capital
Revo Capital is a venture capital firm specializing in early-stage B2B and B2C technology ventures, with a focus on empowering entrepreneurs in Turkey and Eastern Europe. Their investment in Massive Bio suggests a belief in the company's innovative technology and global potential within the health tech sector.
Cavendish Impact Foundation
The Cavendish Impact Foundation is an organization that supports initiatives aimed at positive societal impact. Their participation in Massive Bio's funding round indicates alignment with the company's mission to improve patient access to critical healthcare solutions.
PPP
Public-Private Partnership
What's next for Massive Bio?
With its recent major strategic investment, Massive Bio is poised to further enhance its AI capabilities and expand its market reach. The company's focus on improving patient access to clinical trials, regardless of location or financial status, aligns with critical needs in cancer care and pharmaceutical research. Future growth is expected to involve scaling its operations to serve a broader patient and enterprise customer base, potentially exploring new therapeutic areas beyond oncology, and further developing its data analytics services. This strategic financing will likely fuel advancements in its technology, enabling faster drug discovery and development cycles, and solidifying its position as a leader in AI-driven clinical trial solutions.
See full Massive Bio company page
